Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Study Details
Study Description
Brief Summary
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Hypo-Fractionation Participants will receive one fraction of radiation therapy a day for 5 days each week for 5 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin area under the curve (AUC) 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months. |
Radiation: Hypo-Fractionation
62.5 Gy in 25 fractions of 2.5 Gy/fraction
|
| Active Comparator: Standard-Fractionation Participants will receive one fraction of radiation therapy a day for 5 days each week for 6 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin AUC 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months. |
Radiation: Standard-Fractionation
60 Gy in 30 fractions of 2 Gy/fraction
|
Outcome Measures
Primary Outcome Measures
- Locoregional control (LRC) [From enrollment for up to 7.5 years]
RECIST 1.1
Secondary Outcome Measures
- Acute toxicities [From enrollment for up to 7.5 years]
CTCAE v. 5.0
- Late toxicities [From enrollment for up to 7.5 years]
CTCAE v. 5.0
- Progression free survival (PFS) [From enrollment for up to 7.5 years]
RECIST 1.1
- Overall survival (OS) [From enrollment for up to 7.5 years]
Kaplan-Meier
- Measuring the Impact of Treatment on the Quality of life (QOL) [From enrollment for up to 7.5 years]
EORTC Quality of Life Questionnaire (QLQ)-C30
- Measuring the Impact of Treatment on the Quality of life (QOL) [From enrollment for up to 7.5 years]
QLQ-Lung Cancer (LC)29
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
-
Males and females age ≥ 18 years
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2
-
Measurable disease by RECIST 1.1
-
Women of childbearing potential must have a negative serum pregnancy test within one month prior to initiating treatment
-
Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer (NSCLC)
-
No Positron Emission Tomography (PET)/CT evidence of metastatic disease
-
An MRI of the brain with contrast excluding intracranial metastatic disease (or CT with contrast if MRI is medically contraindicated). An MRI without contrast is only permitted if the subject cannot have contrast for medical reasons
-
If a pleural effusion is present, it must be tapped and confirmed to be cytologically negative. If an effusion is deemed too small to safely tap, the subject will be eligible
-
Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and for 90 days following completion of therapy
-
Adequate organ function per laboratory results
Exclusion Criteria:
-
Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study
-
Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
-
Evidence of severe or systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) that would interfere with study protocol as judged by the investigator
-
Is pregnant or breastfeeding
-
Active connective tissue disorders, such as active lupus or scleroderma
-
Known Acquired Immune Deficiency (HIV (+)/AIDS)
-
Has a known allergic reaction to any excipient contained in the study drug formulations
-
Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment
-
Prior thoracic radiotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The University of Kansas Cancer Center, Westwood Campus | Kansas City | Kansas | United States | 66205 |
| 2 | The University of Kansas Cancer Center, Overland Park Clinic | Overland Park | Kansas | United States | 66210 |
| 3 | KUCC MCA- TUKHS, Saint Francis Hospital | Topeka | Kansas | United States | 66606 |
| 4 | The University of Kansas Cancer Center, North Clinic | Kansas City | Missouri | United States | 64154 |
| 5 | The University of Kansas Cancer Center, Lee's Summit Clinic | Lee's Summit | Missouri | United States | 64064 |
| 6 | The University of Kansas Medical Center | North Kansas City | Missouri | United States | 64116 |
Sponsors and Collaborators
- University of Kansas Medical Center
Investigators
- Principal Investigator: Krishna Reddy, MD, PhD, University of Kansas Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IIT-2021-LU-HypoIMRT